Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 6/2010

01-12-2010

Rheumatoid Vasculitis: Vanishing Menace or Target for New Treatments?

Authors: Christie M. Bartels, Alan J. Bridges

Published in: Current Rheumatology Reports | Issue 6/2010

Login to get access

Abstract

Rheumatoid vasculitis is a rare but serious complication of rheumatoid arthritis. Herein we examine the pathophysiology, epidemiology, clinical diagnosis, and treatment of rheumatoid vasculitis. Seropositivity, specific HLA variations, and tobacco use are among the genetic and environmental predictors of rheumatoid vasculitis. Fortunately, recent reports have noted declines in the prevalence of rheumatoid vasculitis. Nevertheless, proper recognition of systemic manifestations may assist in pathologically confirming the diagnosis, determining the extent of disease, and guiding treatment. Contemporary treatment reports are discussed in the context of the ongoing debate regarding whether new agents may trigger, treat, or even prevent rheumatoid vasculitis. Evolving genetic, histopathologic, and immunologic studies partnered with ongoing clinical experience with biologics offer promise to inform future prevention and treatment of rheumatoid vasculitis.
Literature
1.
Scott DG, Bacon PA, Tribe CR: Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine 1981, 60:288–297.CrossRefPubMed
2.
•• Bartels C, Bell C, Rosenthal A, et al.: Decline in rheumatoid vasculitis prevalence among US veterans: a retrospective cross-sectional study. Arthritis Rheum 2009, 60:2553–2557. This cross-sectional study examined more than 20 years of national data representing more than 37,000 RA patients annually to demonstrate the declining prevalence of rheumatoid vasculitis in the inpatient and outpatient settings, with breakpoints around 2000 suggesting a possible link to new biologic treatments.CrossRefPubMed
3.
Voskuyl AE, Zwinderman AH, Westedt ML, et al.: Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis 1996, 55:190–192.CrossRefPubMed
4.
Turesson C, O’Fallon WM, Crowson CS, et al.: Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003, 62:722–727.CrossRefPubMed
5.
Gorman JD, David-Vaudey E, Pai M, et al.: Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum 2004, 50:3476–3484.CrossRefPubMed
6.
Turesson C, Schaid DJ, Weyand CM, et al.: Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:2776–2783.CrossRefPubMed
7.
Laskaria K, Ahmadi-Simab K, Lamken M, et al.: Are anti-cyclic citrullinated peptide autoantibodies seromarkers for rheumatoid vasculitis in a cohort of patients with systemic vasculitis? Ann Rheum Dis 2010, 69:469–471.CrossRefPubMed
8.
Voskuyl AE, van Duinen SG, Zwinderman AH, et al.: The diagnostic value of perivascular infiltrates in muscle biopsy specimens for the assessment of rheumatoid vasculitis. Ann Rheum Dis 1998, 57:114–117.CrossRefPubMed
9.
Turesson C, Jacobsson LT: Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004, 33:65–72.CrossRefPubMed
10.
Kaye O, Beckers CC, Paquet P, et al.: The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1996, 23:253–257.PubMed
11.
Salvarani C, Macchioni P, Mantovani W, et al.: Extraarticular manifestations of rheumatoid arthritis and HLA antigens in northern Italy. J Rheumatol 1992, 19:242–246.PubMed
12.
Wattiaux MJ, Kahn MF, Thevenet JP, et al.: [Vascular involvement in rheumatoid polyarthritis. Retrospective study of 37 cases of rheumatoid polyarthritis with vascular involvement and review of the literature]. Ann Med Interne (Paris) 1987, 138:566–587.
13.
Genta MS, Genta RM, Gabay C: Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum 2006, 36:88–98.CrossRefPubMed
14.
Ward MM: Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983–2001. Arthritis Rheum 2004, 50:1122–1131.CrossRefPubMed
15.
Watts RA, Lane SE, Scott DG: Decrease over time in the incidence of systemic rheumatoid vasculitis: comment on the article by Turesson et al. Arthritis Rheum 2005, 52:1620–1621; author reply 1621.CrossRefPubMed
16.
Watts RA, Mooney J, Lane SE, Scott DG: Rheumatoid vasculitis: becoming extinct? Rheumatology 2004, 43:920–923.CrossRefPubMed
17.
Turesson C, McClelland RL, Christianson TJ, Matteson EL: No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: results from a community-based study. Arthritis Rheum 2004, 50:3729–3731.CrossRefPubMed
18.
Turesson C, Jacobsson L, Bergstrom U: Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology 1999, 38:668–674.CrossRefPubMed
19.
Turesson C, O’Fallon WM, Crowson CS, et al.: Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002, 29:62–67.PubMed
20.
Puechal X, Said G, Hilliquin P, et al.: Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995, 38:1618–1629.CrossRefPubMed
21.
Caballol Pons N, Montala N, Valverde J, et al.: Isolated cerebral vasculitis associated with rheumatoid arthritis. Joint Bone Spine 2010, 77:361–363.CrossRefPubMed
22.
Zolcinski M, Bazan-Socha S, Zwolinska G, Musial J: Central nervous system involvement as a major manifestation of rheumatoid arthritis. Rheumatol Int 2008, 28:281–283.CrossRefPubMed
23.
Chen KR, Toyohara A, Suzuki A, Miyakawa S: Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 2002, 147:905–913.CrossRefPubMed
24.
Voskuyl AE, Hazes JM, Zwinderman AH, et al.: Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis 2003, 62:407–413.CrossRefPubMed
25.
Coremans IE, Hagen EC, Daha MR, et al.: Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum 1992, 35:1466–1475.CrossRefPubMed
26.
Scott DG, Bacon PA: Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984, 76:377–384.CrossRefPubMed
27.
Espinoza LR, Espinoza CG, Vasey FB, Germain BF: Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. J Am Acad Dermatol 1986, 15:508–512.CrossRefPubMed
28.
Upchurch KS, Heller K, Bress NM: Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol 1987, 17:355–359.CrossRefPubMed
29.
Segal R, Caspi D, Tishler M, et al.: Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988, 31:1182–1185.CrossRefPubMed
30.
Combe B, Didry C, Gutierrez M, et al.: Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Eur J Med 1993, 2:153–156.PubMed
31.
Heurkens AH, Westedt ML, Breedveld FC: Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991, 151:2249–2254.CrossRefPubMed
32.
•• Puechal X, Miceli-Richard C, Mejjad O, et al.: Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 2008, 67:880–884. This article reports on a series of cases of refractory systemic rheumatoid vasculitis treated with anti-TNF therapy that were ascertained via a European survey. Among nine cases, five complete remissions and one partial remission were reported. One patient failed and two stopped treatment.CrossRefPubMed
33.
Armstrong DJ, McCarron MT, Wright GD: Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol 2005, 32:759; author reply 759–760.PubMed
34.
Bartolucci P, Ramanoelina J, Cohen P, et al.: Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126–1132.CrossRef
35.
Garcia-Porrua C, Gonzalez-Gay MA: Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab. Rheumatology (Oxford) 2002, 41:234–235.CrossRef
36.
Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V: Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? J Rheumatol 2006, 33:433; author reply 433–434.PubMed
37.
Unger L, Kayser M, Nusslein HG: Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 2003, 62:587–588.CrossRefPubMed
38.
van der Bijl AE, Allaart CF, Van Vugt J, et al.: Rheumatoid vasculitis treated with infliximab. J Rheumatol 2005, 32:1607–1609.PubMed
39.
•• Ramos-Casals M, Brito-Zeron P, Munoz S, et al.: Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242–251. This article describes a MEDLINE review of all published cases of autoimmune diseases attributed to anti-TNF agents through December 2006, including 113 reported vasculitis cases. The relative reported frequency with specific agents is discussed (etanercept, 59; infliximab, 47; adalimumab, 5; other, 2).CrossRef
40.
•• Guignard S, Gossec L, Bandinelli F, Dougados M: Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol 2008, 26(3 Suppl 49):S23–S29. This large, single-center, retrospective analysis performed a case-cohort study to examine the causal relationship between TNF treatment and vasculitis to conclude that a minority of cases could potentially be attributed to anti-TNF drugs.PubMed
41.
• Hellmann M, Jung N, Owczarczyk K, et al.: Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:929–930. This brief report describes two cases of rheumatoid vasculitis ulcers successfully treated with rituximab following failure of standard DMARDs and prednisone.CrossRef
42.
Maher LV, Wilson JG: Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab. Rheumatology (Oxford) 2006, 45:1450–1451.CrossRef
43.
Kim MJ, Kim HO, Kim HY, Park YM: Rituximab-induced vasculitis: a case report and review of the medical published work. J Dermatol 2009, 36:284–287.CrossRefPubMed
44.
Cambridge G, Stohl W, Leandro MJ, et al.: Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006, 54:723–732.CrossRefPubMed
45.
Jones RB, Ferraro AJ, Chaudhry AN, et al.: A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156–2168.CrossRefPubMed
46.
Eriksson P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005, 257:540–548.CrossRefPubMed
47.
Keogh KA, Ytterberg SR, Fervenza FC, et al.: Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173:180–187.CrossRefPubMed
48.
Albano SA, Santana-Sahagun E, Weisman MH: Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 2001, 31:146–159.CrossRefPubMed
Metadata
Title
Rheumatoid Vasculitis: Vanishing Menace or Target for New Treatments?
Authors
Christie M. Bartels
Alan J. Bridges
Publication date
01-12-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 6/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0130-1

Other articles of this Issue 6/2010

Current Rheumatology Reports 6/2010 Go to the issue

ReviewPaper

Is It All Central Sensitization? Role of Peripheral Tissue Nociception in Chronic Musculoskeletal Pain

ReviewPaper

Orbital Inflammatory Pseudotumors: Etiology, Differential Diagnosis, and Management

ReviewPaper

Pulmonary Vasculitis: Clinical Presentation, Differential Diagnosis, and Management

ReviewPaper

Variations in Brain Gray Matter Associated with Chronic Pain

ReviewPaper

Giant Cell Arteritis: Epidemiology, Diagnosis, and Management

ReviewPaper

Behçet’s Syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits